病因不明癫痫中神经自身抗体的患病率
IMPORTANCE: Autoimmune epilepsy is an underrecognized condition, and its true incidence is unknown. Identifying patients with an underlying autoimmune origin is critical because these patients' condition may remain refractory to conventional antiseizure medications but may respon…
要点
- 病因不明成人癫痫中约三分之一可检出神经自身抗体。
- 抗体阳性者更可能获得良好癫痫控制结局。
- APE评分有助于识别抗体阳性概率高的患者。
核心结论
- 病因不明成人癫痫中相当一部分患者存在提示自身免疫病因的血清抗体。
- 抗体阳性与更好的癫痫控制结局相关,且免疫调节治疗与发作频率降低相关。
研究设计与样本
- 连续纳入因新发或已确立的病因不明癫痫就诊于神经科服务的成人患者。
- 检测血清自身免疫性脑炎抗体以及TPO和GAD65抗体,前瞻性分配基于临床特征的APE评分。
- 数据收集时间为2015年6月1日至2016年6月1日。
主要发现
- 127例入组患者中15例因发现替代诊断被排除,112例纳入分析。
- 39例(34.8%)检出提示潜在自身免疫病因的血清抗体,7例(6.3%)检出超过1种抗体。
- 112例中,15例(13.4%)有TPO-Ab,14例(12.5%)有GAD65-Ab,12例(10.7%)有VGKCc抗体(其中4例LGI1抗体阳性),4例(3.6%)有NMDAR抗体。
- 即使排除TPO-Ab和低滴度GAD65-Ab,仍有23例(20.5%)存在强烈提示自身免疫病因的抗体。
关键数值与推荐
- APE评分是基于临床特征的前瞻性工具,可用于预测血清学阳性。
- 某些临床特征(自主神经功能障碍、神经精神改变、病毒前驱期、面臂肌张力障碍发作或面部运动障碍、MRI内侧颞叶硬化)与血清阳性相关。
临床怎么用
- 对病因不明的成人癫痫患者,应考虑检测神经自身抗体以识别潜在自身免疫病因。
- 可使用APE评分等临床特征工具评估抗体检测前的血清阳性概率。
- 抗体阳性患者可能从免疫调节治疗中获益,并应监测癫痫发作频率变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Autoimmune epilepsy is an underrecognized condition, and its true incidence is unknown. Identifying patients with an underlying autoimmune origin is critical because these patients' condition may remain refractory to conventional antiseizure medications but may respond to immunotherapy. OBJECTIVE: To determine the prevalence of neurological autoantibodies (Abs) among adult patients with epilepsy of unknown etiology. DESIGN, SETTING, AND PARTICIPANTS: Consecutive patients presenting to neurology services with new-onset epilepsy or established epilepsy of unknown etiology were identified. Serum samples were tested for autoimmune encephalitis Abs as well as thyroperoxidase (TPO) and glutamic acid decarboxylase 65 (GAD65) Abs. An antibody prevalence in epilepsy (APE) score based on clinical characteristics was assigned prospectively. Data were collected from June 1, 2015, to June 1, 2016. MAIN OUTCOMES AND MEASURES: Presence of neurological Abs. A score based on clinical characteristics was assigned to estimate the probability of seropositivity prior to antibody test results. Good seizure outcome was estimated on the basis of significant reduction of seizure frequency at the first follow-up or seizure freedom. RESULTS: Of the 127 patients (68 males and 59 females) enrolled in the study, 15 were subsequently excluded after identification of an alternative diagnosis. Serum Abs suggesting a potential autoimmune etiology were detected in 39 (34.8%) cases. More than 1 Ab was detected in 7 patients (6.3%): 3 (2.7%) had TPO-Ab and voltage-gated potassium channel complex (VGKCc) Ab, 2 (1.8%) had GAD65-Ab and VGKCc-Ab, 1 had TPO-Ab and GAD65-Ab, and 1 had anti-Hu Ab and GAD65-Ab. Thirty-two patients (28.6%) had a single Ab marker. Among 112 patients included in the study, 15 (13.4%) had TPO-Ab, 14 (12.5%) had GAD65-Ab, 12 (10.7%) had VGKCc (4 of whom were positive for leucine-rich glioma-inactivated protein 1 [LGI1] Ab), and 4 (3.6%) had N-methyl-D-aspartate receptor (NMDAR) Ab. Even after excluding TPO-Ab and low-titer GAD65-Ab, Abs strongly suggesting an autoimmune cause of epilepsy were seen in 23 patients (20.5%). Certain clinical features, such as autonomic dysfunction, neuropsychiatric changes, viral prodrome, faciobrachial dystonic spells or facial dyskinesias, and mesial temporal sclerosis abnormality on magnetic resonance imaging, correlated with seropositivity. The APE score was a useful tool in predicting positive serologic findings. Patients who were Ab positive were more likely to have good seizure outcome than were patients with epilepsy of unknown etiology (15 of 23 [65.2%] vs 24 of 89 [27.0%]; odds ratio, 4.8; 95% CI, 1.8-12.9; P = .002). In patients who were seropositive, reduction in seizure frequency was associated with use of immunomodulatory therapy. CONCLUSIONS AND RELEVANCE: Among adult patients with epilepsy of unknown etiology, a significant minority had detectable serum Abs suggesting an autoimmune etiology. Certain clinical features (encoded in the APE score) could be used to identify patients with the highest probability of harboring neurological Abs.
引用
- Dubey D, Alqallaf A, Hays R, et al. Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology. JAMA Neurol. 2017. PMID: 28166327. doi:10.1001/jamaneurol.2016.5429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。